This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Health Policy  • Law and Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(2):152.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A change in leadership of the House Energy and Commerce Committee could affect federal health care programs and the health care industry.

House Democrats elected Rep Henry Waxman (D, Calif) by a vote of 137-122 to replace Rep John D. Dingell (D, Mich), the second longest serving representative and the top Democrat on the committee for 28 years. Waxman's ascent raised eyebrows on Capitol Hill in that seniority is typically emphasized in committee leadership.

Rep Henry Waxman (D, Calif) was elected chairman of the House Energy and Commerce Committee, which has jurisdiction over a variety of health-related subjects. (Photo credit: Office of Representative Henry Waxman)

It remains to be seen if Waxman will continue Dingell's agenda, which included probes of pharmaceutical manufacturers and Food and Drug Administration (FDA) oversight. The committee has jurisdiction over energy, the environment, consumer protection, and health care, which includes biomedical research and development, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?